GSK terminates RA project

Report this content

Yesterday, the British pharma giant GSK announced that they are terminating the development of the candidate otilimab for rheumatoid arthritis after it failed to reach the primary endpoint in a phase III study in patients with an inadequate response to biological DMARDs and/or JAK inhibitors.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital


Documents & Links

Quick facts

GSK terminates RA project
Tweet this